<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04997005</url>
  </required_header>
  <id_info>
    <org_study_id>P01.001.16</org_study_id>
    <nct_id>NCT04997005</nct_id>
  </id_info>
  <brief_title>The Medacta International AMIStem-P Post-Marketing Surveillance Study</brief_title>
  <official_title>Prospective, Multicentre, Open Study Evaluating the Performance and Stability of the AMIStem-P Femoral Stem</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medacta International SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medacta International SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Post-Market Surveillance study of AMIStem-P femoral stem prosthesis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2032</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2029</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate</measure>
    <time_frame>10 years</time_frame>
    <description>Kaplan Meier method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome</measure>
    <time_frame>3/6 months, 1, 3, 5 and 10 years</time_frame>
    <description>Harris Hip Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>3/6 months, 1, 3, 5 and 10 years</time_frame>
    <description>Oxford Hip Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic performance of the implants</measure>
    <time_frame>3/6 months, 1, 3, 5 and 10 years</time_frame>
    <description>Presence of radiolucencies, migration, loosening, subsidence, tilt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3/6 months, 1, 3, 5 and 10 years</time_frame>
    <description>EQ-5D score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>intraop, 3/6 months, 1, 3, 5 and 10 years</time_frame>
    <description>Intraoperative and postoperative adverse events</description>
  </secondary_outcome>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Arthrosis</condition>
  <condition>Traumatic Arthritis</condition>
  <condition>Rheumatoid Polyarthritis</condition>
  <condition>Congenital Hip Dysplasia</condition>
  <condition>Avascular Necrosis of the Femoral Head</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AMIStem-P</intervention_name>
    <description>Performance of Total Hip Arthroplasty (THA) with AMIStem-P femoral stem implant</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients requiring Total Hip Arthroplasty and who are suitable to receive Medacta AMIStem-P&#xD;
        femoral stem will be proposed to take part to the current post-market surveillance study&#xD;
        during their pre-operative visit.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a disease (primary coxarthrosis, inflammatory arthritis of the hip,&#xD;
             necrosis of the femoral head, etc.) requiring a total hip replacement&#xD;
&#xD;
          -  Patient eligible to receive an uncemented AMIStem-P femoral stem&#xD;
&#xD;
          -  Patient agreeing to comply with the study requirements&#xD;
&#xD;
          -  Patient willing to provide written informed consent&#xD;
&#xD;
          -  Patient affiliated to a social security system&#xD;
&#xD;
          -  Patients between 18 and 85 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in biomedical research&#xD;
&#xD;
          -  Patients younger than 18 years old&#xD;
&#xD;
          -  Vulnerable adult patients according to article L1121-6 of the French Public Health&#xD;
             Code&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Patients unable to provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandru Nebunescu-Schirliu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Jacques-Puel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denise Falcone</last_name>
    <phone>+41916966060</phone>
    <email>falcone@medacta.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mara Colombo</last_name>
    <phone>+41916966060</phone>
    <email>colombo@medacta.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique de Saint Omer</name>
      <address>
        <city>Blendecques</city>
        <zip>62575</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Meyer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Castres</name>
      <address>
        <city>Castres</city>
        <zip>81108</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karim Basthi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nouvelle Clinique Bordeaux Tondu</name>
      <address>
        <city>Floirac</city>
        <zip>33270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis Tovagliaro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique d'Orange</name>
      <address>
        <city>Orange</city>
        <zip>84100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Hartmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Jacques-Puel</name>
      <address>
        <city>Rodez</city>
        <zip>12000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandru Nebunescu-Schirliu, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Hip Dislocation</mesh_term>
    <mesh_term>Developmental Dysplasia of the Hip</mesh_term>
    <mesh_term>Hip Dislocation, Congenital</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

